Bristol-Myers beats by $0.05, beats on revs; guides FY15 EPS below consensus, revs below consensus
Reports Q4 (Dec) earnings of $0.46 per share, excluding non-recurring items, $0.05 better than the Capital IQ Consensus Estimate of $0.41; revenues fell 4.1% year/year to $4.26 bln vs the $4.03 bln consensus.
- Co issues downside guidance for FY15, sees EPS of $1.55-1.70 vs. $1.73 Capital IQ Consensus Estimate; sees FY15 revs of $14.4-15.0 bln vs. $15.6 bln Capital IQ Consensus Estimate.
- Sees full-year gross margin as a percentage of revenues of approximately 74%
- Reports Q4 Product Revs
- Baraclude $341 mln
- Hepatitis C Franchise $207 mln
- Reyataz $318 mln
- Sustiva Franchise $407 mln
- Erbitux $181 mln
- Sprycel $398 mln
- Yervoy $366 mln
- Abilify $476 mln
- Orencia $476 mln
- Eliquis $281 mln
- Baraclude $341 mln